黑人镰状细胞特质与镰状细胞病患者的急性肾损伤风险
这项多中心观察性研究基于2005年至2018年的登记数据,比较了黑人镰状细胞特质/镰状细胞病患者与正常血红蛋白表型患者的AKI风险。结果显示镰状细胞特质与持续性AKI风险升高相关,镰状细胞病与所有类型AKI风险升高相关,且AKI后eGFR下降更快。
要点
- 镰状细胞特质患者持续性AKI风险增加(aHR 1.64),但AKI和严重AKI风险未显著增加。
- 镰状细胞病患者AKI、严重AKI和持续性AKI风险均显著增加(aHR分别为2.85、2.38、2.50)。
- 镰状细胞特质和镰状细胞病患者发生AKI后eGFR下降速度显著快于正常血红蛋白表型者。
核心结论
- 镰状细胞特质和镰状细胞病与AKI风险升高相关,且AKI与eGFR加速下降相关。
研究设计与样本
- 多中心观察性研究,使用2005年1月至2018年6月的登记数据,纳入成人黑人患者,通过血红蛋白电泳确定镰状细胞特质/病(暴露)和正常血红蛋白表型(参照)。
- 共纳入8968例参照患者、1279例镰状细胞特质患者和254例镰状细胞病患者,中位随访7.6年,平均基线血清肌酐0.8 mg/dl。
主要发现
- 观察到796例AKI事件、452例持续性AKI事件和466例严重AKI事件。
- 与正常血红蛋白表型相比,镰状细胞特质与持续性AKI风险升高相关(校正HR 1.64,95%CI 1.27-2.11),但与AKI(校正HR 1.11,95%CI 0.91-1.36)或严重AKI(校正HR 1.26,95%CI 0.96-1.64)风险无关。
- 镰状细胞病与AKI(校正HR 2.85,95%CI 2.13-3.81)、严重AKI(校正HR 2.38,95%CI 1.65-3.42)和持续性AKI(校正HR 2.50,95%CI 1.68-3.71)风险升高相关。
- AKI后GFR下降在镰状细胞特质患者中加快0.37 ml/min per 1.73 m2 per year(P<0.01),在镰状细胞病患者中加快1.69 ml/min per 1.73 m2 per year(P<0.01)。
临床怎么用
- 对镰状细胞特质和镰状细胞病患者应警惕AKI风险,尤其是镰状细胞病患者需加强肾功能监测。
- 发生AKI后需关注eGFR的加速下降,及早干预以延缓肾功能恶化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Sickle cell trait and sickle cell disease are associated with faster GFR decline compared with normal hemoglobin phenotypes. We sought to compare the AKI risk in sickle cell trait/disease to normal hemoglobin phenotypes and investigate the association between AKI and GFR decline in sickle cell trait/disease. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This multicenter observational study used registry data (January 2005-June 2018) of adult Black patients with sickle cell trait/disease (exposures) and normal hemoglobin phenotype (reference) ascertained by hemoglobin electrophoresis. Outcomes of interest (incident AKI [1.5 times baseline serum creatinine or higher], incident severe AKI [doubling of baseline serum creatinine or higher], and incident sustained AKI [AKI persisting for ≥72 hours]) were adjudicated by chart review and evaluated by Cox regression. The association between AKI and GFR decline (linear mixed models) was also investigated. RESULTS: We identified 8968 reference patients, 1279 patients with sickle cell trait, and 254 patients with sickle cell disease with a median follow-up of 7.6 years and mean baseline serum creatinine of 0.8 mg/dl. We observed 796 AKI events, 452 sustained AKI events, and 466 severe AKI events. Compared with people with a normal hemoglobin phenotype, sickle cell trait was associated with higher risk for sustained AKI (adjusted hazard ratio, 1.64; 95% confidence interval, 1.27 to 2.11), but not AKI (adjusted hazard ratio, 1.11; 95% confidence interval, 0.91 to 1.36) or severe AKI (adjusted hazard ratio, 1.26; 95% confidence interval, 0.96 to 1.64). Sickle cell disease was associated with AKI (adjusted hazard ratio, 2.85; 95% confidence interval, 2.13 to 3.81), severe AKI (adjusted hazard ratio, 2.38; 95% confidence interval, 1.65 to 3.42), and sustained AKI (adjusted hazard ratio, 2.50; 95% confidence interval, 1.68 to 3.71). Post-AKI GFR decline was significantly faster in sickle cell trait (0.37 ml/min per 1.73 m2 per year faster, P<0.01) and disease (1.69 ml/min per 1.73 m2 per year faster, P<0.01) compared with the reference. CONCLUSIONS: Sickle cell trait and disease are associated with higher risk of AKI, which is associated with accelerated decline in eGFR.
引用
- Olaniran KO, Allegretti AS, Zhao SH, et al. Acute Kidney Injury among Black Patients with Sickle Cell Trait and Sickle Cell Disease. Clin J Am Soc Nephrol. 2021. PMID: 33648973. doi:10.2215/CJN.06960520
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。